case_images: PMC4744075_01
case_images: Postoperative magnetic resonance imaging (MRI) in February 2011 . Left: Axial view. Right: Sagittal view
case_images: cureus-0008-000000000446-i01.jpg
case_images: PMC4744075_01_cureus-0008-000000000446-i01.jpg
case_images: FIG1
case_images: Her postoperative magnetic resonance imaging (MRI) is shown in Figure 1.
case_images: Magnetic resonance imaging (MRI) showing cerebellar vermis progression in November 2012. Left: Axial view. Right: Sagittal view
case_images: cureus-0008-000000000446-i02.jpg
case_images: PMC4744075_01_cureus-0008-000000000446-i02.jpg
case_images: FIG2
case_images: Seven months after ending the treatment, a cerebellar relapse in vermis was documented, requiring radiosurgery and temozolomide for four months, when a new progression in the same location was documented (Figure 2).
case_images: PMC4744075_02
case_images: In-111 DTPA octreotide scintigraphy in March 2013 showing moderate expression of somatostatin receptors. Left: 4 hours after infusion. Right: 24 hours after infusion
case_images: cureus-0008-000000000446-i03.jpg
case_images: PMC4744075_02_cureus-0008-000000000446-i03.jpg
case_images: FIG3
case_images: PMC4744075_03
case_images: Stable disease in magnetic resonance imaging (MRI) during octreotide treatment. Left (Top and Bottom): Axial and sagittal view in February 2014. Right (Top and Bottom): Axial and sagittal view in May 2015
case_images: cureus-0008-000000000446-i04.jpg
case_images: PMC4744075_03_cureus-0008-000000000446-i04.jpg
case_images: FIG4
case_images: By May 2015, she had undergone 24 months of treatment with a stable lesion on imaging (Figure 4) and clinical improvement, partially recovering independence and functionality, without any drug-related toxicity.